1242 results about "Tumor growth" patented technology

The present invention relates to a KRASG12D inhibitor and the use thereof. Specifically, provided in the present invention is a compound as shown in formula (I), and the definition of each substituent in the formula is as described in the description. In addition, the present invention further relates to a composition containing the inhibitor and the use thereof. The compound of the present invention has good tumor growth inhibitory activity, and has good safety.

The invention discloses a nano system for tumor radioimmunotherapy and a preparation method and application thereof, and belongs to the technical field of biological medicines.The system modifies bacteria outer membrane vesicles (OMVs) through engineering to enable the bacteria outer membrane vesicles to carry magnetite nanoparticles (Fe3O4NPs) and an ATR inhibitor VE822, the Fenton reaction activity of the Fe3O4NPs and the synergistic effect of the ATR inhibitor for inhibiting DNA damage repair are utilized, and the tumor radioimmunotherapy effect is improved. DNA damage is amplified, DNA damage reaction (DDR) is inhibited, generation of hydroxyl radicals (. OH) under radiation is enhanced, radiation resistance of tumor cells is reduced, immune reaction is reactivated, infiltration of effector T cells to tumors is improved, growth of mice tumors is remarkably inhibited, and an effective strategy is provided for tumor radioimmunotherapy.

The invention discloses a tumor growth prediction and segmentation method based on an adaptive multilayer convolutional neural network. The method comprises the following steps: S1, acquiring a medical image data set containing a tumor region; s2, preprocessing the medical image data set; s3, constructing an adaptive multilayer convolutional neural network model; s4, inputting the preprocessed medical image data set into a self-adaptive multi-layer convolutional neural network model; s5, automatically adjusting the size, the step length and the number of layers of a convolution kernel by the convolution layer; s6, performing supervised learning training on the adaptive multilayer convolutional neural network model through a Dice loss function; s7, outputting a tumor boundary; s8, predicting the growth direction and position of the tumor at the future time point and the possible expansion range of the tumor; s9, dynamically adjusting the convolution kernel size and step length of each layer and weight distribution of an attention mechanism according to a feedback mechanism; and S10, outputting a tumor segmentation result and a growth trend prediction result. According to the invention, the precision and robustness of tumor segmentation and growth trend prediction are improved.

The invention belongs to the technical field of medicines, and particularly discloses application of moss phenol glucoside in preparation of medicines for preventing and / or treating tumors. According to the method, activated CD8 + T cells, MC38-OVA cells and traditional Chinese medicine monomeric compounds are co-cultured, the traditional Chinese medicine monomeric compounds capable of effectively promoting the anti-tumor activity of the CD8 + T cells are selected by utilizing a high-content screening technology, and finally, the experiment is carried out by taking the moss phenol glucoside as a research object. In-vitro experiment results show that the moss phenol glucoside can significantly promote T cell activation, promote release of cell factors such as IFN-gamma and TNF-alpha, and enhance the killing effect of T cells on tumors. A mouse in-vivo tumor-bearing experiment result shows that the moss phenol glucoside can promote the anti-tumor activity of T cells so as to inhibit tumor growth, has no obvious toxic or side effect, can be used for preparing the medicine for preventing and / or treating tumors, and has a potential clinical application prospect and a relatively high economic value.

Provided herein are systems, compositions, and methods for generating immunogenic peptides or epitopes from tumor associated antigens (e.g., in vivo or ex vivo). Polynucleotides (e.g., genes) encoding the tumor associated antigens may be edited at selected target sites by nucleobase editors comprising a catalytically-inactive Cas9 and a cytosine deaminase, leading to the expression of heteroclitic or cryptic peptides that are more immunogenic than the native peptide derived from the tumor associated antigens. The heteroclitic or cryptic peptide elicit strong tumor-specific immune response (e.g., T-cell response or B-cell response), which inhibits tumor growth and metastasis.

The invention belongs to the technical field of preparation of anti-tumor drugs, and particularly relates to a coptis root exosome, an extraction method thereof and application of the coptis root exosome in tumor resistance. The coptis root exosome is extracted from coptis roots, the size of the coptis root exosome is 125nm-135nm, and the coptis root exosome is shaped like a vesicle with a lipid bilayer structure. The coptis root exosome has an excellent anti-tumor effect and can remarkably inhibit tumor growth, and the tumor growth inhibition effect is remarkably superior to that of a common extract berberine in coptis roots.

The invention aims to provide a preparation method and application of a metal-organic nano complex for combined treatment of tumors, belongs to the technical field of antitumor drugs, and adopts a one-pot method to prepare copper-quercetin nanoparticles with uniform morphology. The obtained metal organic complex CQT nanoparticles can be used for X-ray induced sensitization radiotherapy / chemical power combined treatment to promote tumor cell apoptosis, meanwhile, due to introduction of copper ions, the steady state of the copper ions in tumor cells is broken, tumor cell copper death is induced, interaction is formed between copper death and the radiotherapy biological effect, and the tumor cell apoptosis is promoted. The synergistic tumor treatment effect is realized. The novel CQT nano complex for three-in-one treatment of sensitization radiotherapy / chemodynamic therapy / copper death has the function of obviously delaying the growth speed of tumors. The system can maintain good stability and biocompatibility, provides an innovative and efficient treatment potential scheme for intractable tumors clinically lacking specific targets, and improves the long-term prognosis of early metastatic tumors.

The invention relates to application of a GATA3 inhibitor and a PD1 inhibitor in preparation of a medicine for treating breast cancer, and belongs to the technical field of biological medicine. The invention discloses application of a GATA3 inhibitor and a PD1 inhibitor in preparation of a medicine for treating breast cancer. The GATA3 regulates the transcription regulation of IFNbeta by inhibiting the enhancer activity of IFNB1, down-regulates an I-type interferon signal channel, inhibits the secretion of an MHC-I antigen presentation channel and a chemotactic factor CCL5 of breast cancer cells, reduces immune recognition, and achieves the purpose of immune escape. The immunotherapy for inhibiting GATA3 combined with the PD1 inhibitor to treat breast cancer effectively treats breast cancer mice, improves the IFN beta level in the mice, promotes the MHC-I antigen presentation pathway of the mice, improves the CCL5 level in the mice, and improves the CD8 + T cell level in a tumor immune microenvironment, thereby reducing tumor occurrence and inhibiting tumor growth.

The present application relates to an antibody capable of specifically binding to c-Met or antigen-binding fragment thereof, and an immunoconjugate, a pharmaceutical composition and a multispecific molecule comprising the same. The present application further relates to the use of the antibody specifically binding to c-Met or an antigen-binding fragment thereof and the multispecific molecule. Compared with the control antibody, the bispecific antibody or defucosylated bispecific antibody of the present application can block HGF-dependent TKI resistance; block the proliferation and migration of tumor cells induced by HGF, induce ADCC effect, and inhibit tumor growth in vivo.

The invention discloses a Toll-like receptor stimulant-based vaccine adjuvant lipid compound and application thereof, and particularly discloses a compound as shown in a formula (I), a stereoisomer thereof, an N-oxygen compound thereof, a solvate thereof or a pharmaceutically acceptable salt thereof. The mRNA-TLP composition prepared from the adjuvant lipid compound provided by the invention has significantly improved targeting to mouse spleen antigen presenting cells, and can significantly inhibit tumor growth. # imgabs0 #

The invention provides an ultrasonic activated blood coagulation targeting tumor selective prodrug as well as a preparation method and application thereof. The blood coagulation targeting tumor selective prodrug has a structure as shown in a formula I. The blood coagulation targeting tumor selective prodrug can trigger a blood coagulation cascade reaction by utilizing tumor vascular injury generated by ultrasonic induction so as to realize targeted anchoring of the drug and inhibit off-target diffusion of an active drug; meanwhile, the prodrug is activated by ultrasound, so that the limitation of tumor heterogeneity on the activation of the prodrug can be overcome. According to the technical scheme, selective enrichment of active drugs in tumors can be effectively improved, and toxicity caused by drug off-target is reduced while tumor growth is remarkably inhibited.

The present invention provides an enhanced NK cell, its preparation method and application, belonging to the field of biomedical technology. The present invention uses a compound of quercetin, paclitaxel and resveratrol as a culture medium induction additive to pre-treat NK cells, successfully enhancing the killing toxicity of NK cells against human lung cancer cells and effectively inhibiting tumor growth, opening up a new way for the treatment of lung cancer and having important research value and potential clinical application prospects in the field of tumor immunotherapy.

The invention belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating triple negative breast cancer and application thereof. The traditional Chinese medicine composition is prepared from the following main active ingredients in parts by mass: 20 to 40 parts of radix astragali seu hedysari, 10 to 20 parts of rhizoma curcumae, 10 to 20 parts of herba hedyotidis diffusae, 5 to 15 parts of fructus aurantii immaturus, 5 to 15 parts of radix bupleuri, 5 to 15 parts of radix paeoniae alba and 5 to 15 parts of liquorice root. Animal experiments show that the traditional Chinese medicine composition can significantly inhibit tumor growth and pulmonary metastasis of triple-negative breast cancer tumor-bearing mice, increase the proportion of CD8 + T lymphocytes in blood, reduce the proportion of MDSCs, significantly down-regulate the expression of pro-inflammatory cytokines such as IL-6, IL-1alpha, CXCL1 and GM-CSF in serum, and cooperate with PD-L1 immunotherapy to achieve a synergistic effect. And the whole blood and liver and kidney function indexes are in a normal range. Therefore, the traditional Chinese medicine composition disclosed by the invention can be used for effectively inhibiting the tumor growth and pulmonary metastasis of the triple negative breast cancer, remodeling the immune state of an organism and reducing the release of proinflammatory factors, and is safe, reliable, free of obvious liver and kidney toxicity and blood toxicity and small in side effect.

The invention belongs to the field of biomedicine, and particularly relates to polypeptide for targeted blocking of combination of TRIM25 and BRD7 protein and application of the polypeptide. According to the present invention, based on the minimum binding region PRYSPRY structural domain (439 aa-630 aa) of the TRIM25 and the BRD7 protein, the blocking peptide TB16 capable of specifically blocking the mutual binding of the TRIM25 and the BRD7 protein is screened, such that the ubiquitination degradation of the BRD7 is inhibited, and the stability of the BRD7 tumor inhibition protein is improved. The polypeptide drug TB16 can effectively inhibit breast cancer, nasopharynx cancer, ovarian cancer, lung cancer and liver cancer cell proliferation and breast cancer in-vivo tumor growth, has good anti-solid tumor activity, and is expected to become a new anti-tumor targeting drug.

The invention discloses a colorectal cancer radiotherapy sensitization medicine and application thereof, belongs to the field of biological medicine, and particularly relates to a colorectal cancer radiotherapy sensitization medicine which comprises active pharmaceutical ingredients and a solvent, the active pharmaceutical ingredients comprise doxorubicin and a nitrogen-containing compound, the nitrogen-containing compound comprises quinoline-6-carbohydrazide and N-benzyloxymethyl-4-nitroimidazole, and the nitrogen-containing compound comprises quinoline-6-carbohydrazide and The colorectal cancer radiotherapy sensitization medicine disclosed by the invention focuses on a key driving gene FOXP4 for colorectal cancer radiotherapy resistance, and FOXP4 protein is degraded through a ubiquitin-proteasome way, so that not only can the sensitivity of tumor cells to radiotherapy be remarkably improved and tumor growth be inhibited, but also damage to normal tissues is reduced; moreover, the problem of drug resistance easily generated by a traditional method is effectively avoided, the research and development cost is greatly reduced, clinical transformation is accelerated, and the method has a good clinical application prospect.

The invention provides a nano-drug for treating glioma as well as a preparation method and application of the nano-drug, and particularly, the nano-drug comprises a nano-carrier and a carrier drug. The nano-drug can interact with a receptor on a brain endothelial cell, enters a brain tumor microenvironment through an endocytosis way, promotes antigen presenting cell maturation, activates T cell anti-tumor immune response, and effectively inhibits tumor growth.

The invention provides bismuth oxyiodate composite piezoelectric hydrogel as well as a preparation method and application thereof, and belongs to the technical field of hydrogel materials. The bismuth oxyiodate composite piezoelectric hydrogel disclosed by the invention is prepared from the following raw materials in percentage by mass: 0.125 percent to 0.5 percent of first self-assembled oligopeptide, 0.125 percent to 0.5 percent of self-assembled stem cell bone marrow homing peptide, 0 to 0.02 percent of BiOIO3 nanosheets and 98.99 percent to 99.75 percent of a solvent. BiOIO3NSs are integrated into self-assembled stem cell bone marrow homing peptide, the injectable and degradable piezoelectric hydrogel with ultrasonic responsiveness is constructed, BiOIO3NSs shows remarkable piezoelectric catalysis performance, generation of active oxygen is promoted, tumor cell apoptosis is induced, and the piezoelectric hydrogel has the advantages of being capable of being used for preparing the bone marrow homing peptide, capable of being used for preparing the bone marrow homing peptide and capable of being used for preparing the bone marrow homing peptide. The bismuth oxyiodate composite piezoelectric hydrogel disclosed by the invention is a biological material capable of inhibiting the growth and recurrence of tumors and recovering the structure and function of bones to the greatest extent.

The invention discloses an antigen peptide polymer vesicle tumor vaccine as well as a preparation method and application thereof. The antigen peptide polymer vesicle tumor vaccine is obtained by assembling and cross-linking a polymer pre-grafted with antigen peptide and a block polymer and loading an immunologic adjuvant through electrostatic interaction. The vesicle system disclosed by the invention has the advantages of small size, simplicity and controllability in preparation, excellent biocompatibility, high in-vivo circulation stability, targeting of main immune organs, intracellular delivery of antigen peptides and the like. The vesicle nano vaccine displaying the antigen peptide on the surface and encapsulating the immunologic adjuvant can promote dendritic cell maturation and antigen presentation, improve the specific response of mice to tumor-associated antigens, effectively inhibit tumor growth, remarkably prolong the lifetime of tumor-bearing mice and induce a strong immune protection effect, and is high in safety and easy to popularize. A multifunctional'ready-to-use 'nano vaccine concept is embodied, a flexible platform is provided, and different peptide antigens and / or adjuvants can be used for treating different cancers.

The invention discloses an MUC1-CAR-T cell for co-expressing a BTLA / IL-18R chimeric receptor as well as a preparation method and application of the MUC1-CAR-T cell, and belongs to the technical field of biological medicines. The MUC1-CAR-T cell comprises a BTLA / IL-18R chimeric receptor and an MUC1-CAR structure, wherein the BTLA / IL-18R chimeric receptor is a BTLA MUC1 is used as a targeting molecule for CAR-T cell therapy, an extracellular domain of BTLA is connected with a transmembrane domain and an intracellular domain of an IL-18 receptor, and the co-expression BTLA / IL-18R chimeric receptor is designed. Experimental verification shows that the BTLA / IL-18R chimeric receptor can significantly improve the tumor killing ability of MUC1-CAR-T cells, can better inhibit the growth of tumors, and provides a novel immunotherapy strategy for the treatment of pancreatic cancer.

The invention belongs to the technical field of biological medicines, and particularly discloses a nano-engineering T cell membrane coated nano-particle as well as a preparation method and application of the nano-engineering T cell membrane coated nano-particle. Nanoparticles of a specific structure are constructed based on a phospholipid bilayer bionic nanometer platform through a membrane fusion technology, immune clearance caused by phagocytosis of the nanoparticles by macrophages can be avoided through disguise of a T cell membrane, and the blood circulation time is prolonged; the functions of T cells are recovered through specific blocking of immune checkpoint molecules loaded on the immune checkpoint molecules on corresponding immune checkpoint ligands on tumor cells; under ultrasonic radiation, the nano-particles are gradually decomposed and release the sound-sensitive agent to generate a large amount of active oxygen, so that immunogenic death of tumor cells is promoted, more cytotoxic T lymphocytes are recruited to infiltrate into tumor parts, and the recovery of T cell mediated immune response function is facilitated. The synergistic effect of the sound-sensitive agent and the immune checkpoint protein can effectively inhibit tumor growth, induce a long-term immune memory effect and prevent tumor metastasis and recurrence.

The invention discloses a multi-modal image fusion assisted precise tumor needle biopsy guide system, and aims to solve the problem that the traditional needle biopsy guide technology is insufficient in precision. The system innovatively adopts a multi-scale feature fusion algorithm and an adaptive weight fusion strategy, deeply fuses ultrasonic, CT, MRI and other multi-modal images, and comprehensively improves the information amount of the images. Through real-time force feedback and path adjustment, in combination with VR / AR guide interaction, intelligent puncture guide is realized, and safe and accurate operation is guaranteed. Tumor features are extracted by using a deep learning algorithm, accurate tumor recognition and dynamic image analysis are realized, and the tumor growth trend is predicted. According to the system, the precision and success rate of needle biopsy are remarkably improved, the pain of a patient and the medical cost are reduced, powerful support is provided for personalized precise treatment of tumors, and the system has extremely high clinical application value.

The invention discloses a BRIX1 inhibitor and application of the BRIX1 inhibitor in tumor resistance, and particularly discloses a nucleoprotein BRIX1 which is a key regulatory factor of a steady state between ribosome biogenesis and p53 activation. Research results show that inhibition of BRIX1 can induce nucleolus stress to activate p53, so that growth of tumors is inhibited. Besides, the engineered exosome is constructed, the surface of the engineered exosome is decorated with iRGD, and the engineered exosome is loaded with siRNA with BRIX1 specificity and is used for treating cancers.

The invention discloses a novel nucleic acid delivery system based on phosphatidylmitoxantrone as well as a preparation method and application of the novel nucleic acid delivery system based on phosphatidylmitoxantrone, and phosphatidylmitoxantrone (PMA) is used as a novel cationic lipid to construct a novel lipidosome nano nucleic acid delivery system by utilizing the enzymatic response release property and ionizable cationic phospholipid characteristics of phosphatidylmitoxantrone (PMA). PMA not only can be used as a novel cationic lipid entrapped nucleic acid, but also can be used as an auxiliary lipid component to promote nucleic acid delivery, so that the synergistic anti-tumor effect of nucleic acid and mitoxantrone is realized. The system can respond to high expression of phospholipase D (PLD) in tumor tissues, promote hydrolysis of PMA and release chemotherapeutic drug mitoxantrone, dual functions of nucleic acid delivery and drug release are achieved, the purpose of double-target inhibition of tumor growth is achieved, and a new strategy is provided for cancer treatment.

The invention provides a nucleic acid aptamer agonist conjugate as well as a preparation method and application thereof. The nucleic acid aptamer agonist conjugate is prepared by coupling a nucleic acid aptamer, a connexon and an STING agonist, the nucleic acid aptamer agonist conjugate can be used as a medicine to recognize a target spot on the surface of a tumor cell in a targeted manner and enter the cell to start a cGAS-STING signal channel so as to realize an anti-tumor effect. The variety of STING agonists and the variety of connexons are also screened, so that the aptamer agonist conjugate not only has the advantages of easiness in transmembrane and cell entry, strong tumor permeability, long half-life period, small toxic and side effects and the like, but also has a strong inhibition effect on triple-negative breast cancer. The aptamer agonist conjugate can also be combined with an immune checkpoint blocking therapy to further realize long-acting and efficient inhibition of tumor growth.

The invention discloses application of an azetidine compound in preparation of a medicine for preventing and treating triple-negative breast cancer, and belongs to the technical field of biological medicine. By adopting an international common triple-negative breast cancer modeling method, the scheme shows that the compound can effectively inhibit the tumor growth state of nude mouse triple-negative breast cancer, inhibit STAT3 705 site tyrosine phosphorylation and induce tumor cells to generate G2-M phase arrest and apoptosis, and has remarkable prevention and treatment effects on triple-negative breast cancer; the compound is expected to become a novel medicine for treating triple-negative breast cancer.

The invention discloses a hepatobiliary tumor follow-up visit data processing service system, and relates to the technical field of hepatobiliary tumor follow-up visit data processing. A data collection module is used for collecting hepatobiliary tumor growth and change conditions of a current patient in a current follow-up visit period; the tumor volume change rate OBL, the tumor growth speed OTS and the tumor growth predicted value OY are sequentially calculated and output, the change trend of the liver and gall tumors of the current patient is observed, basic data are provided for follow-up visit diagnosis and treatment, and the current patient is in the next follow-up visit period through a data prediction processing module. And taking the tumor growth predicted value OY of the last follow-up period as an input value of the tumor volume Ostart when follow-up of the next follow-up period starts to form continuous calculation of follow-up, so that efficient and accurate processing and analysis of tumor data are realized, the prediction accuracy is improved, and errors generated by prediction are corrected and adjusted in time; and more accurate treatment suggestions are provided for patients.

The invention discloses an anti-tumor combined pharmaceutical composition and application thereof, and belongs to the technical field of biological medicine. The combined pharmaceutical composition comprises an OTUD4 inhibitor and a ferroptosis inducer or regorafenib which serve as active ingredients, and the OTUD4 inhibitor inhibits expression of OTUD4 in a targeted mode or causes function deficiency of OTUD4 and promotes occurrence of ferroptosis in tumor cells. The combined pharmaceutical composition provided by the invention more effectively inhibits tumor growth by synergistically increasing the oxidative stress level in cells, thereby playing a stronger anti-tumor effect. The combined treatment scheme provided by the invention provides a new thought for tumor treatment, and particularly in patients ineffective or drug-resistant to single-drug treatment, targeted inhibition of OTUD4 and regorafenib can effectively overcome drug resistance and significantly inhibit tumor growth.

The invention discloses an application of a selenium-rich lactobacillus rhamnosus microbial inoculum in preparation of antitumor drugs, and relates to the field of biotechnology and tumor treatment, the selenium-rich lactobacillus rhamnosus is prepared through a selenium-rich fermentation process, inorganic selenium difficult to absorb can be converted into an organic form suitable for body absorption, and bioavailability is improved. The selenium-enriched lactobacillus rhamnosus disclosed by the invention can inhibit tumor growth in an oral administration manner, and a new carrier is provided for probiotic anti-tumor research.

The invention belongs to the field of biomedicine, and particularly relates to application of Ikbkb inhibited or knocked-out macrophages in preparation of breast cancer radiotherapy sensitizing drugs. The inventor of the invention proves the effect of the macrophage of which the Ikbkb is inhibited or knocked out in breast cancer radiotherapy for the first time. Compared with the strategy of mainly depending on small molecule drugs or antibodies in the prior art, the tumor growth can be more effectively inhibited after the macrophages in the tumor microenvironment are transformed and the Ikbkb knockout engineered macrophages are subjected to combined radiotherapy, and a brand new solution is provided for overcoming breast cancer radiotherapy resistance.

The invention discloses a traditional Chinese medicine composition for treating breast cancer complicated with anxiety disorder as well as a preparation method and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition is mainly prepared from the following raw material medicines: astragalus membranaceus, herba epimedii, ligusticum wallichii, semen boitae, acanthopanax, rhizoma drynariae, selfheal, arisaema cum bile, turtle shell, nigrum fruit, salvia chinensis and artemisia apiacea. The invention further discloses a preparation method of the traditional Chinese medicine composition, a pharmaceutical preparation and application. Pharmacodynamic experiments prove that the traditional Chinese medicine composition can remarkably inhibit tumor growth of anxiety tumor-bearing mice and improve anxiety behavioral indexes, achieves dual treatment targets of tumor resistance and emotion regulation, and is particularly suitable for middle and advanced breast cancer combined anxiety patient groups needing long-term treatment.